Rhumbline Advisers Humacyte, Inc. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Humacyte, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 110,919 shares of HUMA stock, worth $602,290. This represents 0.0% of its overall portfolio holdings.
Number of Shares
110,919
Previous 59,061
87.8%
Holding current value
$602,290
Previous $183,000
190.71%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding HUMA
# of Institutions
137Shares Held
31.3MCall Options Held
323KPut Options Held
582K-
Black Rock Inc. New York, NY7.14MShares$38.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.73MShares$25.7 Million0.0% of portfolio
-
State Street Corp Boston, MA2.87MShares$15.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$10.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.6MShares$8.68 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $559M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...